 | • レポートコード：GIR201103520 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、疾患修飾性抗リウマチ治療薬の世界市場を調査対象にし、疾患修飾性抗リウマチ治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（非ステロイド系抗炎症治療薬、ステロイド系抗炎症治療薬、徐放性薬、免疫学的製剤）、用途別分析（製薬業、病院・クリニック、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：AbbVie、Merck、Roche Holding AG、Amgen、Bristol-Myers Squibb、Pfizer、Eli Lilly and Company、Johnson & Johnson、Novartis International AG、UCB S.A. ・メーカー別販売量、売上、市場シェア ・疾患修飾性抗リウマチ治療薬の地域別市場分析 ・疾患修飾性抗リウマチ治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・疾患修飾性抗リウマチ治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・疾患修飾性抗リウマチ治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・疾患修飾性抗リウマチ治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・疾患修飾性抗リウマチ治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・疾患修飾性抗リウマチ治療薬の種類別市場規模2015-2020：非ステロイド系抗炎症治療薬、ステロイド系抗炎症治療薬、徐放性薬、免疫学的製剤 ・疾患修飾性抗リウマチ治療薬の用途別市場規模2015-2020：製薬業、病院・クリニック、その他 ・疾患修飾性抗リウマチ治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Disease-Modifying Antirheumatic Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Disease-Modifying Antirheumatic Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Disease-Modifying Antirheumatic Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Disease-Modifying Antirheumatic Drug market has been segmented into
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
By Application, Disease-Modifying Antirheumatic Drug has been segmented into:
Pharmaceutical Industry
Hospital and Clinic
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Disease-Modifying Antirheumatic Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Disease-Modifying Antirheumatic Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Disease-Modifying Antirheumatic Drug market.
The report offers in-depth assessment of the growth and other aspects of the Disease-Modifying Antirheumatic Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Disease-Modifying Antirheumatic Drug Market Share Analysis
Disease-Modifying Antirheumatic Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Disease-Modifying Antirheumatic Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Disease-Modifying Antirheumatic Drug sales, revenue and market share for each player covered in this report.
The major players covered in Disease-Modifying Antirheumatic Drug are:
AbbVie
Merck
Roche Holding AG
Amgen
Bristol-Myers Squibb
Pfizer
Eli Lilly and Company
Johnson & Johnson
Novartis International AG
UCB S.A.
Among other players domestic and global, Disease-Modifying Antirheumatic Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Disease-Modifying Antirheumatic Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Disease-Modifying Antirheumatic Drug, with price, sales, revenue and global market share of Disease-Modifying Antirheumatic Drug in 2018 and 2019.
Chapter 3, the Disease-Modifying Antirheumatic Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Disease-Modifying Antirheumatic Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Disease-Modifying Antirheumatic Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Disease-Modifying Antirheumatic Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Disease-Modifying Antirheumatic Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Disease-Modifying Antirheumatic Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Market Analysis by Application
1.3.1 Overview: Global Disease-Modifying Antirheumatic Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Overview of Global Disease-Modifying Antirheumatic Drug Market
1.4.1 Global Disease-Modifying Antirheumatic Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie SWOT Analysis
2.1.4 AbbVie Product and Services
2.1.5 AbbVie Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck SWOT Analysis
2.2.4 Merck Product and Services
2.2.5 Merck Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche Holding AG
2.3.1 Roche Holding AG Details
2.3.2 Roche Holding AG Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche Holding AG SWOT Analysis
2.3.4 Roche Holding AG Product and Services
2.3.5 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Amgen SWOT Analysis
2.4.4 Amgen Product and Services
2.4.5 Amgen Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pfizer SWOT Analysis
2.6.4 Pfizer Product and Services
2.6.5 Pfizer Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Eli Lilly and Company
2.7.1 Eli Lilly and Company Details
2.7.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Eli Lilly and Company SWOT Analysis
2.7.4 Eli Lilly and Company Product and Services
2.7.5 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Johnson & Johnson SWOT Analysis
2.8.4 Johnson & Johnson Product and Services
2.8.5 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis International AG
2.9.1 Novartis International AG Details
2.9.2 Novartis International AG Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis International AG SWOT Analysis
2.9.4 Novartis International AG Product and Services
2.9.5 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 UCB S.A.
2.10.1 UCB S.A. Details
2.10.2 UCB S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 UCB S.A. SWOT Analysis
2.10.4 UCB S.A. Product and Services
2.10.5 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Disease-Modifying Antirheumatic Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Disease-Modifying Antirheumatic Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Disease-Modifying Antirheumatic Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
4.3 Europe Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
4.5 South America Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Country
5.1.1 North America Disease-Modifying Antirheumatic Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Disease-Modifying Antirheumatic Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
5.3 Canada Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Disease-Modifying Antirheumatic Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
6.3 UK Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
6.4 France Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
6.5 Russia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
6.6 Italy Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Disease-Modifying Antirheumatic Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7.3 Japan Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7.4 Korea Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7.5 India Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
7.7 Australia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Country
8.1.1 South America Disease-Modifying Antirheumatic Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Disease-Modifying Antirheumatic Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Disease-Modifying Antirheumatic Drug Sales and Market Share by Type (2015-2020)
10.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2015-2020)
11 Global Disease-Modifying Antirheumatic Drug Market Segment by Application
11.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
11.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2015-2020)
11.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Disease-Modifying Antirheumatic Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Disease-Modifying Antirheumatic Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025)
12.2.2 Europe Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025)
12.2.4 South America Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025)
12.3 Disease-Modifying Antirheumatic Drug Market Forecast by Type (2021-2025)
12.3.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Disease-Modifying Antirheumatic Drug Market Share Forecast by Type (2021-2025)
12.4 Disease-Modifying Antirheumatic Drug Market Forecast by Application (2021-2025)
12.4.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Disease-Modifying Antirheumatic Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Disease-Modifying Antirheumatic Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Disease-Modifying Antirheumatic Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AbbVie Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie Disease-Modifying Antirheumatic Drug Major Business
Table 9. AbbVie Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 10. AbbVie SWOT Analysis
Table 11. AbbVie Disease-Modifying Antirheumatic Drug Product and Services
Table 12. AbbVie Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Merck Basic Information, Manufacturing Base and Competitors
Table 14. Merck Disease-Modifying Antirheumatic Drug Major Business
Table 15. Merck Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 16. Merck SWOT Analysis
Table 17. Merck Disease-Modifying Antirheumatic Drug Product and Services
Table 18. Merck Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 20. Roche Holding AG Disease-Modifying Antirheumatic Drug Major Business
Table 21. Roche Holding AG Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 22. Roche Holding AG SWOT Analysis
Table 23. Roche Holding AG Disease-Modifying Antirheumatic Drug Product and Services
Table 24. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Amgen Basic Information, Manufacturing Base and Competitors
Table 26. Amgen Disease-Modifying Antirheumatic Drug Major Business
Table 27. Amgen Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 28. Amgen SWOT Analysis
Table 29. Amgen Disease-Modifying Antirheumatic Drug Product and Services
Table 30. Amgen Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 32. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Major Business
Table 33. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 34. Bristol-Myers Squibb SWOT Analysis
Table 35. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product and Services
Table 36. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Pfizer Basic Information, Manufacturing Base and Competitors
Table 38. Pfizer Disease-Modifying Antirheumatic Drug Major Business
Table 39. Pfizer Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 40. Pfizer SWOT Analysis
Table 41. Pfizer Disease-Modifying Antirheumatic Drug Product and Services
Table 42. Pfizer Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 44. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Major Business
Table 45. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 46. Eli Lilly and Company SWOT Analysis
Table 47. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product and Services
Table 48. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 50. Johnson & Johnson Disease-Modifying Antirheumatic Drug Major Business
Table 51. Johnson & Johnson Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 52. Johnson & Johnson SWOT Analysis
Table 53. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product and Services
Table 54. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Novartis International AG Basic Information, Manufacturing Base and Competitors
Table 56. Novartis International AG Disease-Modifying Antirheumatic Drug Major Business
Table 57. Novartis International AG Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 58. Novartis International AG SWOT Analysis
Table 59. Novartis International AG Disease-Modifying Antirheumatic Drug Product and Services
Table 60. Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 62. UCB S.A. Disease-Modifying Antirheumatic Drug Major Business
Table 63. UCB S.A. Disease-Modifying Antirheumatic Drug Total Revenue (USD Million) (2017-2018)
Table 64. UCB S.A. SWOT Analysis
Table 65. UCB S.A. Disease-Modifying Antirheumatic Drug Product and Services
Table 66. UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Disease-Modifying Antirheumatic Drug Sales by Manufacturer (2018-2019) (MT)
Table 68. Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Disease-Modifying Antirheumatic Drug Sales by Regions (2015-2020) (MT)
Table 70. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Regions (2015-2020)
Table 71. Global Disease-Modifying Antirheumatic Drug Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Disease-Modifying Antirheumatic Drug Sales by Countries (2015-2020) (MT)
Table 73. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Countries (2015-2020)
Table 74. North America Disease-Modifying Antirheumatic Drug Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020)
Table 76. Europe Disease-Modifying Antirheumatic Drug Sales by Countries (2015-2020) (MT)
Table 77. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Countries (2015-2020)
Table 78. Europe Disease-Modifying Antirheumatic Drug Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales by Regions (2015-2020) (MT)
Table 80. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Disease-Modifying Antirheumatic Drug Sales by Countries (2015-2020) (MT)
Table 83. South America Disease-Modifying Antirheumatic Drug Sales Market Share by Countries (2015-2020)
Table 84. South America Disease-Modifying Antirheumatic Drug Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Countries (2015-2020) (MT)
Table 87. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020)
Table 90. Global Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 91. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2015-2020)
Table 92. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2015-2020) (USD Million)
Table 93. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2015-2020)
Table 94. Global Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 95. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2015-2020)
Table 96. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Regions (2021-2025) (MT)
Table 97. Global Disease-Modifying Antirheumatic Drug Market Share Forecast by Regions (2021-2025)
Table 98. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2021-2025) (MT)
Table 99. Global Disease-Modifying Antirheumatic Drug Market Share Forecast by Type (2021-2025)
Table 100. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2021-2025)
Table 101. Global Disease-Modifying Antirheumatic Drug Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Disease-Modifying Antirheumatic Drug Picture
Figure 2. Global Sales Market Share of Disease-Modifying Antirheumatic Drug by Type in 2019
Figure 3. Non-Steroidal Anti-Inflammatory Drugs Picture
Figure 4. Steroidal Anti-Inflammatory Drugs Picture
Figure 5. Slow Acting Drug Picture
Figure 6. Immunological Preparation Picture
Figure 7. Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2018
Figure 8. Pharmaceutical Industry Picture
Figure 9. Hospital and Clinic Picture
Figure 10. Other Picture
Figure 11. Global Disease-Modifying Antirheumatic Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Disease-Modifying Antirheumatic Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturer in 2019
Figure 32. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Disease-Modifying Antirheumatic Drug Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Disease-Modifying Antirheumatic Drug Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 37. Global Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions (2015-2020)
Figure 39. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions in 2018
Figure 40. North America Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
Figure 41. Europe Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
Figure 43. South America Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020)
Figure 45. North America Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Countries (2015-2020)
Figure 47. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Countries in 2018
Figure 48. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries in 2018
Figure 50. United States Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 51. Canada Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 52. Mexico Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 53. Europe Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries in 2019
Figure 56. Germany Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 57. UK Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 58. France Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 59. Russia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 60. Italy Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 61. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions 2019
Figure 64. China Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 65. Japan Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 66. Korea Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 67. India Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 68. Southeast Asia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 69. South America Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Disease-Modifying Antirheumatic Drug Sales Market Share by Countries in 2019
Figure 71. South America Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries in 2019
Figure 72. Brazil Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 73. Argentina Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 74. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 79. Egypt Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 80. Turkey Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 81. South Africa Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2015-2020) (MT)
Figure 82. Global Disease-Modifying Antirheumatic Drug Sales and Growth Rate (2021-2025) (MT)
Figure 83. Global Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025) (MT)
Figure 85. Europe Sales Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025) (MT)
Figure 86. Asia-Pacific Sales Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025) (MT)
Figure 87. South America Sales Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025) (MT)
Figure 88. Middle East & Africa Sales Disease-Modifying Antirheumatic Drug Market Forecast (2021-2025) (MT)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
アルツハイマー病治療薬の世界市場 2020年 Market Overview The Alzheimer's Disease Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…- ベーチェット病治療薬の世界市場 2020年 Market Overview The global Behcet Disease Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Behcet Disease Drug marke…
- シャルコー・マリー・トゥース病I型治療薬の世界市場 2020年 Market Overview The global Charcot-Marie-Tooth Disease Type I A Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cha…
- シャーガス病治療薬の世界市場 2020年 Market Overview The global Chagas Disease Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Chagas Disease Drug marke…
- 自殺防止薬の世界市場 2020年 Market Overview The global Anti-Suicide Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anti-Suicide Drug market re…